Phase Ia/Ib study of RS-0139, a novel tumor-targeted delivery of docetaxel, in patients with recurrent, locally advanced, or metastatic non-small cell lung cancer (NSCLC)

Simple item page
dc.contributor.authorOrer, H. S.
dc.contributor.authorNomak, G.
dc.contributor.authorOksuzoglu, B.
dc.contributor.authorSenturk, R.
dc.contributor.authorEralp, Y.
dc.contributor.authorYumuk, F.
dc.contributor.authorNomak, H.
dc.contributor.authorSanyal, R.
dc.date.accessioned2023-02-21T12:38:05Z
dc.date.available2023-02-21T12:38:05Z
dc.date.issued2022-01-01
dc.description.issue7
dc.description.issue7
dc.description.pagesSEP
dc.description.volume33
dc.identifier.doi10.1016/j.annonc.2022.07.1876
dc.identifier.urihttps://hdl.handle.net/11443/2335
dc.identifier.urihttp://dx.doi.org/10.1016/j.annonc.2022.07.1876
dc.identifier.wosWOS:000866211601462
dc.relation.ispartofANNALS OF ONCOLOGY
dc.titlePhase Ia/Ib study of RS-0139, a novel tumor-targeted delivery of docetaxel, in patients with recurrent, locally advanced, or metastatic non-small cell lung cancer (NSCLC)
dc.typeArticle

Files

Collections

WOS